Fig. 1From: Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)Study Schema of SHAMROCK study. Abbreviations: RDI RNA disruption index, T-DXd trastuzumab deruxtecan, iCR imaging complete responseBack to article page